NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for neurodegenerative diseases such as ALS, AD, and PD. The company was incorporated on February 13, 2017, as a private company limited by shares under the laws of the State of Israel. Its principal executive offices are located at 11 Hamenofim, Herzliya, Israel. In December 2021, NeuroSense Therapeutics Ltd. completed its initial public offering on The Nasdaq Capital Market, receiving net proceeds of approximately $9.9 million after deducting underwriting discounts, commissions, and offering expenses. The company's Ordinary Shares and Warrants are traded on The Nasdaq Capital Market under the symbols "NRSN" and "NRSNW," respectively. Capital expenditures for the years ended December 31, 2025, and 2024 were approximately $8,000 and $3,000, respectively, primarily involving the purchase of equipment. The company aims to address the significant unmet medical needs in neurodegenerative diseases, which currently have limited effective therapeutic options. For instance, the average annual cost of ALS is $180,000 per patient, with an estimated annual burden on the U.S. healthcare system exceeding $1 billion.